Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

for the European College of Neuropsychopharmacology (ECNP) Bipolar Disorders Network

Résultat de recherche: Articleexamen par les pairs

20 Citations (Scopus)

Résumé

Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substantial burden on society, the research activity in BD is much smaller than its economic impact appears to demand. There is a consensus that the accurate identification of the underlying pathophysiology for BD is fundamental to realize major health benefits through better treatment and preventive regimens. However, to achieve these goals requires coordinated action and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, and rapid translation of research findings into development and testing of better and more specific treatments. To this end, we here propose that only a large-scale coordinated action can be successful in integrating international big-data approaches with real-world clinical interventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, which could bring government, industry and philanthropy together in common cause. A global initiative for BD research would come at a highly opportune time given the seminal advances promised for our understanding of the genetic and brain basis of the disease and the obvious areas of unmet clinical need. Such an endeavour would embrace the principles of open science and see the strong involvement of user groups and integration of dissemination and public involvement with the research programs. We believe the time is right for a step change in our approach to understanding, treating and even preventing BD effectively.

Langue d'origineEnglish
Pages (de-à)121-136
Nombre de pages16
JournalEuropean Neuropsychopharmacology
Volume36
DOI
Statut de publicationPublished - juill. 2020

Note bibliographique

Funding Information:
We thank Chris Chang for input on the description of the ENIGMA project. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health in the UK. Ole A. Andreassen is together with Paolo Fusar-Poli co-chairing the Prevention of Severe Mental Disorders (PSMD) cluster, which is supported by the European Brain Research Area project. EBRA has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825348 .

Funding Information:
Supported by unrestricted grants from the ECNP network program, Research Council of Norway (#223273), and European Union's Horizon 2020 research and innovation programme (#847776). The concept and content of the paper were outlined and discussed on the ECNP Bipolar Disorder Network meeting in Copenhagen 2019. MM, OBS, EV, GG, OAA drafted the manuscript. All authors revised and approved the final version, OAA has received speaker honorarium from Lundbeck, and is a consultant to HealthLytix. LVK declares having received consultancy fees from Lundbeck in the past three years. AB declares having received travelling fees and funding for IITs from Otsuka and Janssen. REN has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva A/S, and Eli Lilly and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda, and Medivir. AGP has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Alter, Angelini, Exeltis, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), the Basque Governement, the Stanley Medical Research Institute. RWL has received research grant from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Sunovion and Sage. AR as served on advisory boards of Janssen, SAGE, Shire/Takeda and Medice; has received speaker's honoraria from Janssen, Medice, Shire/Takeda, Servier, and Neuraxpharm; and has received research grants from Medice. GG is a NIHR Emeritus Senior Investigator, holds shares in P1vital and P1Vital products and has served as consultant, advisor or CME speaker in the last 3 years for Allergan, Angelini, Compass pathways, MSD, Janssen, Lundbeck (/Otsuka or /Takeda), Medscape, Minerva, P1Vital, Pfizer, Sage, Servier, Shire, Sun Pharma. All other authors declare no conflict of interest. We thank Chris Chang for input on the description of the ENIGMA project. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health in the UK. Ole A. Andreassen is together with Paolo Fusar-Poli co-chairing the Prevention of Severe Mental Disorders (PSMD) cluster, which is supported by the European Brain Research Area project. EBRA has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825348.

Funding Information:
OAA has received speaker honorarium from Lundbeck, and is a consultant to HealthLytix. LVK declares having received consultancy fees from Lundbeck in the past three years. AB declares having received travelling fees and funding for IITs from Otsuka and Janssen. REN has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva A/S, and Eli Lilly and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda, and Medivir. AGP has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Alter, Angelini, Exeltis, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), the Basque Governement, the Stanley Medical Research Institute. RWL has received research grant from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Sunovion and Sage. AR as served on advisory boards of Janssen, SAGE, Shire/Takeda and Medice; has received speaker's honoraria from Janssen, Medice, Shire/Takeda, Servier, and Neuraxpharm; and has received research grants from Medice. GG is a NIHR Emeritus Senior Investigator, holds shares in P1vital and P1Vital products and has served as consultant, advisor or CME speaker in the last 3 years for Allergan, Angelini, Compass pathways, MSD, Janssen, Lundbeck (/Otsuka or /Takeda), Medscape, Minerva, P1Vital, Pfizer, Sage, Servier, Shire, Sun Pharma. All other authors declare no conflict of interest.

Funding Information:
Supported by unrestricted grants from the ECNP network program, Research Council of Norway (#223273), and European Union's Horizon 2020 research and innovation programme (#847776).

Publisher Copyright:
© 2020

ASJC Scopus Subject Areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Empreinte numérique

Plonger dans les sujets de recherche 'Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action'. Ensemble, ils forment une empreinte numérique unique.

Citer